Chapter 01
The surgeon's daughter
Ozlem Tureci grew up in a Turkish medical family in Germany. Her father's path back into medicine after migration became an early lesson in maintaining expertise even when institutions do not immediately recognize it.
She studied medicine and became drawn to immunology: the possibility that the body's own systems could be taught to identify and fight disease.
Chapter 02
A shared scientific project
Tureci met Ugur Sahin while both were working as physicians and researchers. Their collaboration joined her emphasis on evidence and translation with a shared conviction that immune responses could be directed against cancer.
They co-founded Ganymed Pharmaceuticals and later BioNTech. Both companies were built around years of platform research that preceded broad commercial recognition.
Chapter 03
The company nobody understood
BioNTech began in 2008 with individualized cancer immunotherapy at its center. Messenger RNA offered a way to give cells temporary instructions, but instability, delivery, and immune-response challenges made the platform difficult and easy to dismiss.
By early 2020, the company had accumulated scientific infrastructure, manufacturing knowledge, and teams capable of testing multiple candidates quickly. The response to COVID-19 was rapid because the underlying work was not new.
Chapter 04
Project Lightspeed
In January 2020, Sahin and Tureci concluded that the new coronavirus could become a pandemic and redirected substantial company resources toward a vaccine. BioNTech developed multiple candidates in parallel and partnered with Pfizer for global trials, manufacturing, and distribution.
The resulting vaccine compressed a process normally measured in years without eliminating clinical trials or regulatory review. Speed came from overlapping work, accepting financial risk, and using a platform refined through years of cancer research.
Chapter 05
The record after the emergency
The vaccine changed BioNTech's scale and visibility, but Tureci continued to frame the company through its longer mission in cancer and individualized medicine.
Her record is therefore larger than one pandemic product: patient platform building, scientific work before recognition, and the ability to redirect a mature body of knowledge when a new threat arrives.